about
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen als...
Read More
155.51
-1.23
(-0.78%)
1.4M
XNAS Volume
XNAS 07 Nov, 2025 4:30 PM (EST)
High Financial Strength
Affordable Valuation
Technically Moderately Bullish
Strong Performer
These stock companies have strong financials and are affordably priced. They also score high in quality and technical aspects which makes them a favourite amongst investors.
View Similar
Embed DVM
Biogen Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..